After a phase 3 push the livmoniplimab plan falters.
ApexOnco Front Page
Recent articles
The company discontinues one of its two KRAS G12D degraders.
A pipeline update reveals the dropping of RC248, after cMet and Claudin18.2 ADCs disappeared earlier.
TLX101 follows Ipax-1 with an apparent success in an academic trial.
TAR-210's latest non-muscle invasive bladder cancer phase 3 setting is post-BCG.
The company scraps nemvaleukin after the latest failure, of Artistry-6.
J&J's new anti-ENPP3 ADC appears – and then disappears – from a clinical study listing.
Meanwhile, Akeso challenges Moderna and BioNTech with an mRNA neoantigen play.
